about
The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey.Investigating preferences for support with life after stroke: a discrete choice experiment.Multiple imputation of multiple multi-item scales when a full imputation model is infeasible.Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence.Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey.Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria.Renal transplant patients' preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment.Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical TrialCost-effectiveness of HLA-B*15:02 screening in Malaysia.Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.Rare disease prevention and treatment: the need for a level playing field.New advice on switching antiepileptic drugs might be a false economy.Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment MethodsCost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic ArthritisAdalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCTAttitudes towards epilepsy in the UK population: Results from a 2018 national surveyPatient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic DrugsCost-Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkReply
P50
Q31166578-576F75E6-6EBC-40FA-85BC-994463E64DA2Q35089256-835CA680-7306-4AE3-8073-BD0556ADD218Q35904272-7D5DDBEC-685E-4329-B963-171F9BBFD85BQ36243674-A2A5912C-FF38-4C8D-A865-3312BDCC4A77Q38395019-1EC7CDA3-D12F-4EE4-B4CB-EE71EBA3CC21Q38692558-5A7326C5-11ED-4C97-A679-A5684C2BE36CQ38777644-AB3EE56E-A89D-44A6-BC9B-3084A356F095Q39029027-93F5E172-FE02-4112-9E1C-58BB6F833CDFQ39197284-18E71BBD-85FE-49E4-B882-684BB34E492DQ42284359-A14310AD-99CC-473D-9089-7F69D99CCB6FQ42363097-75C195CE-1A8F-4926-98DB-6B244A28C36AQ47624981-4DA082E0-FEFE-4F4A-BA5A-3377EE55F9A3Q47731199-53B81B77-4CF7-43D4-AEF7-A9076B3E6D09Q50071892-93A14873-23ED-4AAB-8342-D2B23C00FDBCQ54433624-F4A69C3C-EF9B-4375-B6EB-A725D076F033Q57773939-51F2715E-232B-4222-A15E-C3215504558CQ58565522-33EC0F15-AF55-4EFB-9EB0-D26444271E3BQ64092580-EB63C96E-A87F-48A8-9956-C3A1870A2C27Q90808504-9960ED2C-03F4-47B2-A9A1-20F4CDE23EF8Q91381970-F3E4EBC5-0FC0-4B41-B727-DDE3E90452D7Q93351962-DAE27EC0-E22F-49F5-A502-8C999AF267D9Q95407161-99EA4D95-8412-4773-A87E-6E41F3475B17
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Catrin Plumpton
@ast
Catrin Plumpton
@en
Catrin Plumpton
@es
Catrin Plumpton
@nl
type
label
Catrin Plumpton
@ast
Catrin Plumpton
@en
Catrin Plumpton
@es
Catrin Plumpton
@nl
prefLabel
Catrin Plumpton
@ast
Catrin Plumpton
@en
Catrin Plumpton
@es
Catrin Plumpton
@nl
P106
P1153
25960268100
P31
P496
0000-0003-2710-9199